Here we report the results of the phase II part of LUME-Meso (ClinicalTrials.gov identifier: NCT01907100), an ongoing phase II/III study designed to evaluate the safety and efficacy of standard ...
Lume-meso: A double-blind, randomized, phase II/III study of nintedanib (N) + pemetrexed (P)/cisplatin (C) followed by maintenance N versus placebo + P/C followed by maintenance placebo for patients ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. In a recent update, NovoCure Ltd.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results